Shares of Legend Biotech Co. (NASDAQ:LEGN – Get Free Report) have earned an average recommendation of “Buy” from the thirteen ratings firms that are covering the company, MarketBeat.com reports. Thirteen research analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $81.78.
Several research firms have weighed in on LEGN. Royal Bank of Canada reissued an “outperform” rating and issued a $86.00 price target on shares of Legend Biotech in a research note on Friday, September 27th. BMO Capital Markets restated an “outperform” rating and issued a $90.00 price objective on shares of Legend Biotech in a research report on Wednesday, July 3rd. Scotiabank boosted their price objective on shares of Legend Biotech from $70.00 to $76.00 and gave the company a “sector outperform” rating in a research report on Monday, August 12th. TD Cowen decreased their price objective on shares of Legend Biotech from $71.00 to $67.00 and set a “buy” rating on the stock in a research report on Monday, July 15th. Finally, HC Wainwright restated a “buy” rating and issued a $73.00 price objective on shares of Legend Biotech in a research report on Monday, September 30th.
Check Out Our Latest Research Report on LEGN
Hedge Funds Weigh In On Legend Biotech
Legend Biotech Stock Performance
NASDAQ LEGN opened at $49.58 on Tuesday. Legend Biotech has a 52-week low of $38.60 and a 52-week high of $70.78. The company has a debt-to-equity ratio of 0.25, a quick ratio of 4.78 and a current ratio of 4.84. The company has a market capitalization of $9.04 billion, a P/E ratio of -38.14 and a beta of 0.10. The company has a fifty day moving average of $53.12 and a 200-day moving average of $49.94.
Legend Biotech (NASDAQ:LEGN – Get Free Report) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.49. The company had revenue of $186.50 million during the quarter, compared to the consensus estimate of $125.25 million. Legend Biotech had a negative net margin of 62.50% and a negative return on equity of 23.20%. The firm’s revenue was up 154.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.27) EPS. As a group, equities research analysts predict that Legend Biotech will post -1.46 EPS for the current fiscal year.
About Legend Biotech
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
Featured Articles
- Five stocks we like better than Legend Biotech
- What does consumer price index measure?
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- CD Calculator: Certificate of Deposit Calculator
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- How Investors Can Find the Best Cheap Dividend Stocks
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.